Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Chua

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
American Journal of Respiratory and Critical Care Medicine|July 11, 2026
Mycophenolate and Azathioprine in Fibrotic Interstitial Lung DiseaseJanelle Vu Pugashetti, Adelle S Jee, Andrew R Yu, et al.
Respirology (Carlton, Vic.)|January 13, 2022
Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitisClaudio Macaluso, Cristina Boccabella, Maria Kokosi, et al.
The Lancet. Infectious Diseases|January 19, 2019
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort studyHilary S Whitworth, Amarjit Badhan, Aime A Boakye, et al.
ERJ Open Research|October 27, 2018
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practiceSophie V Fletcher, Mark G Jones, Elizabeth A Renzoni, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Journal of Thoracic Disease|December 11, 2025
Survey of physicians' approaches to the clinical evaluation of interstitial lung disease in Singapore (SoPhoCLES)Felicia S W Teo, Gin Tsen Chai, Su Ying Low, et al.
The European Respiratory Journal|November 9, 2019
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung diseaseVeronica Alfieri, Ernesto Crisafulli, Dina Visca, et al.
Thorax|March 11, 2021
Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction scoreFelix Chua, Rama Vancheeswaran, Adrian Draper, et al.
Respirology (Carlton, Vic.)|September 29, 2022
Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort studyTimothy J W Dawes, Colm McCabe, Konstantinos Dimopoulos, et al.
BMJ Open|December 21, 2025
Epidemiology and disease burden of connective tissue disease-associated interstitial lung disease (CTD-ILD) in Asia: a systematic review and meta-analysis protocolFelix Chua, Sivasangari Subramaniam, Wei Hong Lai, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
American Journal of Respiratory and Critical Care Medicine|July 11, 2026
Mycophenolate and Azathioprine in Fibrotic Interstitial Lung DiseaseJanelle Vu Pugashetti, Adelle S Jee, Andrew R Yu, et al.
Respirology (Carlton, Vic.)|January 13, 2022
Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitisClaudio Macaluso, Cristina Boccabella, Maria Kokosi, et al.
The Lancet. Infectious Diseases|January 19, 2019
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort studyHilary S Whitworth, Amarjit Badhan, Aime A Boakye, et al.
ERJ Open Research|October 27, 2018
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practiceSophie V Fletcher, Mark G Jones, Elizabeth A Renzoni, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Journal of Thoracic Disease|December 11, 2025
Survey of physicians' approaches to the clinical evaluation of interstitial lung disease in Singapore (SoPhoCLES)Felicia S W Teo, Gin Tsen Chai, Su Ying Low, et al.
The European Respiratory Journal|November 9, 2019
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung diseaseVeronica Alfieri, Ernesto Crisafulli, Dina Visca, et al.
Thorax|March 11, 2021
Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction scoreFelix Chua, Rama Vancheeswaran, Adrian Draper, et al.
Respirology (Carlton, Vic.)|September 29, 2022
Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort studyTimothy J W Dawes, Colm McCabe, Konstantinos Dimopoulos, et al.
BMJ Open|December 21, 2025
Epidemiology and disease burden of connective tissue disease-associated interstitial lung disease (CTD-ILD) in Asia: a systematic review and meta-analysis protocolFelix Chua, Sivasangari Subramaniam, Wei Hong Lai, et al.
Pageof 8